Trial · NCT03129126
Registered outcomes13
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
1 to 13 of 13
Download this page as JSON| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Patient Reported Mean episodes of visible blood | At every patient visit, up to 2 weeks following initial treatment | Pre-post changes in mean episodes of visible blood in urine (or blood clots) on 3-day bladder diaries at baseline and primary endpoint |
| Secondary | Urine Dipstick Mean episodes of Visible Blood | At every patient visit, up to 2 weeks following initial treatment | Mean episodes of visible blood in urine (or blood clots) and urine dipstick for quantitative grading of microscopic hematuria on bladder diaries |
| Secondary | Mean urine hemoglobin concentration | At every patient visit, up to 2 weeks following initial treatment | Mean urine hemoglobin concentration |
| Secondary | Urine analysis with microscopy | At every patient visit, up to 2 weeks following initial treatment | Urine analysis with microscopy including red blood cells per high power field test |
| Secondary | Whole blood Add to dictionary levels | At every patient visit, up to 2 weeks following initial treatment | Whole blood tacrolimus levels |
| Secondary | Blood chemistry and liver function test | At every patient visit, up to 2 weeks following initial treatment | Blood chemistry and liver function test |
| Secondary | Patient Reported Global Response Assessment Survey Score | At every patient visit, up to 2 weeks following initial treatment | Changes in Global Response Assessment (GRA) |
| Secondary | Patient Reported Urinary frequency | At every patient visit, up to 2 weeks following initial treatment | Changes in urinary frequency and incontinence measured on diaries |
| Secondary | Bladder Cystoscopy | At initial treatment and on final patient visit, up to 2 weeks following initial treatment | Cystoscopic changes in bladder |
| Secondary | Patient Reported Health Related Quality of Life Survey Score | At every patient visit, up to 2 weeks following initial treatment | Changes in Health Related Quality of Life (HRQOL) scores |
| Secondary | Post void residual urine volume | At every patient visit, up to 2 weeks following initial treatment | Post void residual urine volume |
| Secondary | Patient Reported Pain and Urgency | At every patient visit, up to 2 weeks following initial treatment | Change in pain and urgency 10 cm visual analog scales (VAS) |
| Secondary | Incidence of Treatment-Emergent Adverse Events | At every patient visit, up to 2 weeks following initial treatment | Safety data will be collected by ongoing monitoring of adverse events, during the entire duration of the study, including need for blood transfusion, bladder irrigation, emergency room visit, hospitalization, urinary catheterization, and/or surgery in addition to patient reporting of changes in urinary frequency, hematuria/ clots, incontinence, spasm or discomfort. |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT03129126/registered